AbbVie to Present Data from expansive Portfolio at American College of Gastroenterology Annual Scientific Meeting
Data illustrates AbbVie’s commitment to furnishing exploration and innovative results that support cases with high complaint burden and unmet need
Oral donations address treatment of moderate to severe Crohn’s complaint, including efficacity and safety issues from the SKYRIZI ®( risankizumab- rzaa) vital clinical program as well as late- breaking Phase 3 investigational data from the upadacitinib 52- week conservation trial
Bill donations include an analysis of the impact of CREON ®( pancrelipase) on case- reported diurnal symptoms in exocrine pancreatic insufficiency due to habitual pancreatitis or pancreatic surgery
AbbVie( NYSE ABBV) moment blazoned that 26 objectifications across its gastroenterology portfolio will be presented at the American College of Gastroenterology( ACG) Annual Scientific Meeting, October 21- 26, 2022, in Charlotte,N.C., and nearly.
” At AbbVie, our courteously designed clinical programs concentrate on creating bodies of substantiation that elevate our understanding of vulnerable- mediated GI conditions,” said Celine Goldberger, MD, PhD, vice chairman, head of US Medical Affairs, AbbVie.” introducing exploration presented at ACG illustrates our fidelity to enhancing scientific understanding of how to ameliorate complaint exertion and shape the future of GI operation, beyond only managing symptoms and aiming to ameliorate norms of care.”
AbbVie will partake oral donations from the SKYRIZI ®( risankizumab- rzaa) and RINVOQ ®( upadacitinib) Phase 3 clinical trial programs including late- breaking data. Notable bill data include data on SKYRIZI ®, LINZESS ®( linaclotide), RINVOQ ®( upadacitinib) and CREON ®( pancrelipase), as well as the impact of seditious bowel complaint. A database with all 26 AbbVie objectifications accepted for donation at ACG 2022 can be set up then.
AbbVie objectifications presented at the 2022 ACG Annual Scientific Meeting are outlined below.
AbbVie abstracts presented at the 2022 ACG Annual Scientific Meeting are outlined below.
|Abstract Title||Presentation DetailsAll times ET|
|Clinical and Endoscopic Improvements with Risankizumab Induction and Maintenance Dosing Versus Placebo are Observed Irrespective of Number of Prior Failed Biologics||Oral Presentation; Plenary Session 3A – IBD / Late Breaking Abstracts; October 25; 2:35 to 2:45 PM|
|Fatigue Improvement Correlates with Reductions in Work Productivity Impairment and Related Indirect Cost in Patients with Crohn’s disease: Post Hoc Analysis of Two Phase 3 Induction Trials||October 24; 10:00 AM to 12:00 PM|
|52-Weeks Risankizumab Subcutaneous Maintenance Dosing is Efficacious and Well Tolerated in Patients with Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction||Oral Presentation; Plenary Session 3A – IBD / Late Breaking Abstracts; October 25; 2:35 to 2:45 PM|
|Baseline and Early Predictors of Response to Risankizumab Induction and Maintenance Treatment in Patients with Moderate to Severe Crohn’s Disease||October 25; 10:00 AM to 12:00 PM|
|Induction and Maintenance Treatment with Risankizumab is Superior to Placebo for Achieving Symptomatic Relief in Patients with Moderate to Severe Crohn’s Disease||Oral Presentation; Plenary Session 3A – IBD / Late Breaking Abstracts; October 25; 2:15 to 2:25 PM|
|Risankizumab Results in Improvements in Disease Activity Scores in Patients with Crohn’s Disease: Post-hoc Analysis of the Phase 3 Induction and Maintenance Studies||October 24; 10:00 AM to 12:00 PM|
|Efficacy and Safety of Upadacitinib Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Results from a Randomized Phase 3 U-EXCEL Study||October 24; 10:00 AM to 12:00 PM|
|Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Results from a Randomized Phase 3 U-ENDURE Maintenance Study||Oral Presentation; Plenary Session 3A – IBD / Late Breaking Abstracts; October 25; 3:25 to 3:35 PM|
|Benefit-risk Assessment of Upadacitinib Treatment in Patients with Moderately to Severely Active Ulcerative Colitis||October 23; 5:00 to 7:00 PM|
|Benefits of High Versus Low Dose Upadacitinib as Maintenance Treatment in Ulcerative Colitis Patients Who Were Responders to 8-week Induction with Upadacitinib: Results from the U-ACHIEVE Phase 3 Maintenance Trial||Oral Presentation; Presidential Plenary Session 1; October 24; 8:00 to 8:12 AM|
|Matching-Adjusted Indirect Comparison of Upadacitinib Versus Vedolizumab in Patients with Moderate to Severe Ulcerative Colitis||October 24; 10:00 AM to 12:00 PM|
|Efficacy and Safety of Upadacitinib in Patients with Moderately to Severely Active Ulcerative Colitis Receiving 16 weeks’ Extended Induction Treatment Followed by 52 weeks’ Maintenance Treatment in the U-ACHIEVE/U-ACCOMPLISH Trials||Oral Presentation; Plenary Session 4A – Colon / IBD; October 26; 9:30 to 9:40 AM|
|Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Final Results from the Phase 3 U-ACHIEVE Maintenance Study||October 24; 10:00 AM to 12:00 PM|
|Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study||October 24; 3:00 to 5:00 PM|
|Impact of Inflammatory Burden on Efficacy of Upadacitinib Maintenance Therapy in Ulcerative Colitis: Results from the Phase 3 U-ACHIEVE Study||October 25; 10:00 AM to 12:00 PM|
|Symptoms and Laboratory Values as Proxies for Endoscopic and Histologic Clinical Endpoints in Ulcerative Colitis: A Mediation Analysis Based on Upadacitinib Phase 3 Induction Trials||October 24; 3:00 to 5:00 PM|
|Inflammatory Bowel Disease (IBD)|
|A Longitudinal Evaluation of Patients with Inflammatory Bowel Disease in Puerto Rico||October 25; 3:00 to 5:00 PM|
|Economic Costs and Trends in Inflammatory Bowel Disease-related Hospitalizations and Surgery in the United States||October 25; 3:00 to 5:00 PM|
|Racial and Ethnic Differences in Diagnosed Prevalence, Specialist Visits, and Treatment Utilization of Inflammatory Bowel Disease: Retrospective Analysis of US Claims Data||October 25; 3:00 to 5:00 PM|
|Evaluation of Quality-of-Care Indicators Among Patients with Crohn’s Disease and Ulcerative Colitis in the United States: 2019–2020||October 24; 3:00 to 5:00 PM|
|Irritable Bowel Syndrome with Constipation (IBS-C)|
|Predictors of Placebo Response in Patients with Irritable Bowel Syndrome and Constipation: A Post-hoc Analysis from Pooled Phase 2b/3 Studies Assessing the Safety and Efficacy of Linaclotide||October 24; 10:00 AM to 12:00 PM|
|Disease Burden and Care-seeking Behavior of Patients with Irritable Bowel Syndrome with Constipation (IBS-C) in the United States||October 23; 5:00 to 7:00 PM|
|Chronic Idiopathic Constipation (CIC)|
|Impact of Abdominal Symptoms in Patients with Chronic Idiopathic Constipation (CIC) in the United States||October 23; 5:00 to 7:00 PM|
|Irritable Bowel Syndrome with Diarrhea (IBS-D)|
|Burden of Disease in Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) in the United States||October 23; 5:00 to 7:00 PM|
|Exocrine Pancreatic Insufficiency (EPI)|
|Development of a Clinical Screening Tool for Exocrine Pancreatic Insufficiency (EPI) in Patients with Chronic Pancreatitis (CP)||October 24; 3:00 to 5:00 PM|
|Impact of Pancrelipase on Patient-Reported Daily Symptoms in Patients with Exocrine Pancreatic Insufficiency due to Chronic Pancreatitis or Pancreatic Surgery: Analysis of Randomized Trial Patient-Reported Daily Symptoms||October 24; 3:00 to 5:00 PM|
SKYRIZI( risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of SKYRIZI encyclopedically.
Use of RINVOQ( upadacitinib) in Crohn’s complaint isn’t approved and its safety and efficacity haven’t been estimated by nonsupervisory authorities.
LINZESS( linaclotide) is part of a collaboration between AbbVie and Ironwood medicinals to partake development and commercialization of LINZESS in the United States.
AbbVie’s charge is to discover and deliver innovative drugs that break serious health issues moment and address the medical challenges of hereafter. We strive to have a remarkable impact on people’s lives across several crucial remedial areas immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio.